Two years of approved digital health applications in Germany - Perspectives and experiences of general practitioners with an affinity for their use.

Digital health applications general practitioner mHealth primary care telemedicine

Journal

The European journal of general practice
ISSN: 1751-1402
Titre abrégé: Eur J Gen Pract
Pays: England
ID NLM: 9513566

Informations de publication

Date de publication:
Dec 2023
Historique:
entrez: 15 3 2023
pubmed: 16 3 2023
medline: 17 3 2023
Statut: ppublish

Résumé

Since 2020, physicians in Germany can prescribe approved digital health applications (DHAs) with the costs covered by the health system. There has so far been a lack of studies on attitudes and experiences amongst GPs in using DHAs. The aim was to elucidate the experiences and observations of GPs that have used DHAs in health care and to examine the conditions necessary for DHAs to gain a foothold in primary care according to the GPs. In 2022, 96 qualitative semi-standardised interviews were conducted with German GPs with experience in prescribing DHAs. The GPs were all organised in digitalisation-oriented physicians' associations. Fifty-four interviews were carried out in person and 42 by phone. The data were analysed according to qualitative content analysis. Unlike health apps, the interviewees saw DHAs as reliable tools for enhancing the relationship between GPs and their patients. They saw the DHAs they had been prescribing as useful and reported various benefits, including improvements in compliance, mobility, information for patients and weight reduction. The physicians also saw room for further improvement (usability, gamification, training, information sources). Interviewees saw the inclusion of DHAs in evidence-based guidelines as a major step forward. The interviewees rated DHAs favourably regarding healthcare potential and as safer and more reliable than conventional health apps. Many saw benefits to healthcare from using such applications. From the interviewees' point of view, DHAs can be integrated more effectively into patient care.

Sections du résumé

BACKGROUND UNASSIGNED
Since 2020, physicians in Germany can prescribe approved digital health applications (DHAs) with the costs covered by the health system. There has so far been a lack of studies on attitudes and experiences amongst GPs in using DHAs.
OBJECTIVES UNASSIGNED
The aim was to elucidate the experiences and observations of GPs that have used DHAs in health care and to examine the conditions necessary for DHAs to gain a foothold in primary care according to the GPs.
METHODS UNASSIGNED
In 2022, 96 qualitative semi-standardised interviews were conducted with German GPs with experience in prescribing DHAs. The GPs were all organised in digitalisation-oriented physicians' associations. Fifty-four interviews were carried out in person and 42 by phone. The data were analysed according to qualitative content analysis.
RESULTS UNASSIGNED
Unlike health apps, the interviewees saw DHAs as reliable tools for enhancing the relationship between GPs and their patients. They saw the DHAs they had been prescribing as useful and reported various benefits, including improvements in compliance, mobility, information for patients and weight reduction. The physicians also saw room for further improvement (usability, gamification, training, information sources). Interviewees saw the inclusion of DHAs in evidence-based guidelines as a major step forward.
CONCLUSION UNASSIGNED
The interviewees rated DHAs favourably regarding healthcare potential and as safer and more reliable than conventional health apps. Many saw benefits to healthcare from using such applications. From the interviewees' point of view, DHAs can be integrated more effectively into patient care.

Identifiants

pubmed: 36919621
doi: 10.1080/13814788.2023.2186396
pmc: PMC10026738
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2186396

Références

J Med Internet Res. 2019 May 21;21(5):e13117
pubmed: 31115340
Gesundheitswesen. 2022 Aug;84(8-09):696-700
pubmed: 33957698
J Med Internet Res. 2017 Oct 24;19(10):e324
pubmed: 29066429
Internist (Berl). 2022 Mar;63(3):245-254
pubmed: 35037948
Eur J Gen Pract. 2020 Dec;26(1):140-145
pubmed: 33025820
BMJ. 2015 May 07;350:h2336
pubmed: 25953643
Inn Med (Heidelb). 2022 Dec;63(12):1298-1306
pubmed: 36279007
JMIR Mhealth Uhealth. 2019 Jun 3;7(6):e13199
pubmed: 31199343
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021 Oct;64(10):1213-1219
pubmed: 34550412
Lancet Digit Health. 2019 Jun;1(2):e58-e59
pubmed: 33323231
Fam Pract. 2019 Mar 20;36(2):214-218
pubmed: 29873708
Arthritis Res Ther. 2021 Apr 19;23(1):121
pubmed: 33874994
JMIR Mhealth Uhealth. 2021 Nov 23;9(11):e33012
pubmed: 34817385
JMIR Med Inform. 2016 Apr 06;4(2):e11
pubmed: 27052805
Eur J Gen Pract. 2020 Dec;26(1):108-118
pubmed: 32757859
JMIR Mhealth Uhealth. 2020 Jul 30;8(7):e17447
pubmed: 32729839
Lancet Digit Health. 2022 Mar;4(3):e200-e206
pubmed: 35216754
JMIR Mhealth Uhealth. 2019 Mar 28;7(3):e12179
pubmed: 30920383
Digit Health. 2022 Jul 3;8:20552076221104672
pubmed: 35811758
Stud Health Technol Inform. 2019 Aug 21;264:1919-1920
pubmed: 31438407
JMIR Mhealth Uhealth. 2018 Apr 17;6(4):e88
pubmed: 29666045

Auteurs

Julian Wangler (J)

Centre for General and Geriatric Medicine, University Medical Centre Mainz, Mainz, Germany.

Michael Jansky (M)

Centre for General and Geriatric Medicine, University Medical Centre Mainz, Mainz, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH